| Home : Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon |
|
Oct 01
2019 |
Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon |
|
STOCKHOLM, Oct. 1, 2019 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company's lead compound Nefecon, currently in... |
|
|
|
| Source:https://prnmedia.prnewswire.com:443/news-releases/positive-interactions-with-ema-provide-route-to-conditional-marketing-authorization-of-lead-candidate-nefecon-300928379.html |
| |
|
Related News
|
» Vieworks to expand 25MP CMOS area scan camera lineup
» Change of the Election Committee of Castellum AB Before the AGM 2020
|
